Deepbrain Ethereum
Publish: 2021-05-20 18:07:33
1.
CBBADDACBBDAA
2. There is no best, only targeted. Heavy strengthening is aimed at large calibre rifles, while Samurai suits and PLA bulletproof vests are large calibre and small calibre, but the effect is not very good. Others say that the sniper's lucky probability is very important. In fact, the gunner's luck is also very important. The so-called lucky is that your bullet has a certain probability to directly ignore the armor and cause direct damage to the enemy. The sniper, needless to say, must have killed him with one shot, while the rifleman means that he has already died before the other party's body armor is broken. If you use the latest PLA body armor and PLA uniform, you may be more defensive. If you use the enhanced explosion-proof suit and the fourth generation body armor, you will be more lucky. In fact, the difference is not too big. I don't know about hiding attributes. In addition, even if you buy a helmet, it is only installed on the head of the Scout. As a sniper, you don't enjoy the protection of the helmet. That is to say, if you are a professional sniper, you might as well buy a hat with attributes. The latest fishing cap adds luck and movement speed, and the previous school Beret adds defense and movement speed.... I hope it can help you
3. DBS, namely deep brain stimulation, provides a reversible method for the treatment of Parkinson's disease. A sustained release agent, Tris buffered saline. It means 3-ethanolamine buffered saline solution or 3-hydroxymethylaminomethane buffered saline solution. See more answers & gt& gt;
4. What is deep brain stimulation therapy< Deep
brain stimulation (DBS) is commonly known as "brain pacemaker". By implanting the brain pacemaker into the body, doctors can send out weak electric pulses to stimulate the motor related nerve nuclei in the brain, and regulate the abnormal brain nerve signals that cause Parkinson's disease symptoms, so as to alleviate the symptoms of Parkinson's disease and enable the patients to recover their self-care and work ability.
brain stimulation (DBS) is commonly known as "brain pacemaker". By implanting the brain pacemaker into the body, doctors can send out weak electric pulses to stimulate the motor related nerve nuclei in the brain, and regulate the abnormal brain nerve signals that cause Parkinson's disease symptoms, so as to alleviate the symptoms of Parkinson's disease and enable the patients to recover their self-care and work ability.
5. 1. Early treatment of PD
the DA neurons in the substantia nigra striatum system in the early stage of PD can compensate for the increase of DA synthesis. Physiotherapy (massage, hydrotherapy) and physical therapy (joint activity, walking, balance and language exercise, facial expression muscle exercise) are recommended to strive for the cooperation of patients' families, encourage patients to take more active exercise, and delay the drug treatment time as far as possible. If the disease affects the daily life and work of patients, drug treatment is needed< Drug therapy
2. Drug therapy is still the main treatment for PD at present. It can not prevent the development of PD by restoring the balance of Da and ACh neurotransmitter system in striatum, using anticholinergic and improving Da neurotransmitter function drugs to improve symptoms
principle of medication:
① starting from small dose, slowly increasing, try to use small dose to achieve satisfactory curative effect
② indivialized treatment plan, according to the patient's age, type and degree of symptoms, employment situation, drug price and affordability
3. Drugs should not be added blindly, should not be stopped suddenly, and should be taken for life< In recent years, adjuvant drugs such as Dr agonist, MAO-B inhibitor, catechol-O-methyltransferase (COMT) and so on, combined with compound dopa, can enhance the curative effect, rece the fluctuation of symptoms, and rece the dose of compound dopa, but the curative effect is not ideal when used alone. Therefore, we should weigh the advantages and disadvantages, and choose appropriate combination drugs
(1) anticholinergic drugs: effective for tremor and ankylosis, poor for motor retardation, suitable for younger patients with tremor. Artene was given orally 1-2mg, three times a day; Kemadrin 2.5mg orally, three times a day, graally increased to 20 ~ 30mg / d. Other drugs, such as benzotropin, cycrimine and Akineton, have similar effects to antam. Side effects include dry mouth, blurred vision, constipation, dysuria, and hallucinations and delusions in severe cases. It is forbidden in patients with glaucoma and prostatic hypertrophy, which can affect the memory function. It should be used with caution in elderly patients
(2) amantadine: it can promote the release of DA in nerve endings, prevent the reuptake, and has anticholinergic effect. It is a glutamate antagonist, which may have neuroprotective effect. It can slightly improve hyperactivity, rigidity and tremor, and can be used alone or in combination with antam in the early stage. The initial dose was 50mg, 2-3 times / D, and increased to 100mg, 2-3 times / d after one week, generally no more than 300mg / D, and no more than 200mg / D for the elderly. The effect can last for several months to one year. Less side effects, such as restlessness, blurred consciousness, lower limb reticular plaques, ankle edema and arrhythmia, should be used with caution in patients with renal insufficiency, epilepsy, severe gastric ulcer and liver disease, and should not be used in lactating women. Its derivative memantine hydrochloride can also be used
(3) L-dopa and compound L-dopa: L-dopa is an effective drug or gold indicator in the treatment of PD. As a precursor of Da, it can pass through the blood-brain barrier and be decarboxylated into Da after being ingested by brain dopaminergic neurons. It can improve symptoms and has a special effect on hypokinesia. Because more than 95% of L-dopa decarboxylate into DA in the peripheral blood, only about 1% of it enters the brain through BBB. In order to rece the peripheral side effects and enhance the curative effect, the compound preparation (compound L-dopa) made of L-dopa and DCI in the ratio of 4:1 is often used, and the dosage is 3 / 4 less than that of L-dopa
formulation of compound L-dopa: including standard tablets, controlled-release tablets, water-soluble tablets, etc. Standard tablets such as Madopar and Sinemet: ① Madopar was composed of L-dopa and Benserazide in the ratio of 4:1, Madopar 250 was L-dopa 200mg + Benserazide 50mg, Madopar 125 was L-dopa 100mg + Benserazide 25mg; The components of domestic dopasazide capsules are the same as those of Madopar; ② The ratio of L-dopa to carbidopa was 4 ∶ 1< There are two kinds of controlled-release agents:
① sinemetcr: L-dopa 200mg + carbidopa 50mg. The single-layer molecular matrix structure is added in the preparation. The drug is continuously dissolved to achieve sustained-release effect. The peak plasma concentration is reached 120-150min after oral administration; There is a scratch in the middle of the tablet, which can be divided into half tablets to maintain the sustained-release characteristics
② Madopar HBS: L-dopa 100mg + Benserazide 25mg and special excipients. When the capsules are dissolved, a hydration layer is formed on the surface of the drug matrix, which is graally released through dispersion
the water-soluble tablets were made up of 100 mg of L-dopa and 25 mg of Benserazide. Its characteristics are easy to dissolve in water, easy to take orally, rapid absorption, quickly reaching the treatment threshold concentration, so that PD patients in the "closed" state can quickly improve symptoms in a short time (about 10 minutes), and the effect maintenance time is basically the same as the standard tablets. The dosage form is suitable for PD patients with dysphagia or nasogastric tube insertion, inability to exercise in the morning, delayed "on" period, prolonged "off" period in the afternoon and dystonia at the end of the dosage
timing of medication: when to start the treatment of compound L-dopa is still controversial, and long-term medication will proce complications such as efficacy decline, symptom fluctuation and dyskinesia. Generally, the medication should be determined according to the patient's age, nature of work, type of disease, etc. Young patients should postpone the use of L-dopa and try to use other anti PD drugs in the early stage. When patients have to use L-dopa e to occupational requirements, they should be combined with other drugs to rece the dose of compound L-dopa. The elderly patients can choose L-dopa early, because the chance of motor complications is relatively less, and the tolerance of combined medication is poor
medication method: starting from a small dose, graally increasing according to the condition, maintaining with the lowest effective dose
① standard tablets: the dosage of compound L-dopa was 62.5mg (1 / 4 tablets), 2-3 times / D, and graally increased to 125mg, 3-4 times / D as needed; The maximum dose is not more than 250 mg, 3-4 times a day; Fasting (1 hour before meal or 2 hours after meal) was effective
② controlled release tablets: it has the advantages of recing the times of taking medicine, stable effective blood concentration, long action time and controlling the fluctuation of symptoms; The disadvantages are low bioavailability and slow onset. When standard tablets are converted into controlled-release tablets, the daily dose should be increased and taken in advance; It is suitable for patients with symptoms fluctuation or early mild disease
③ water soluble tablet: it is easy to dissolve in water, quickly absorbed, takes effect in 10 minutes, and has the same effect maintenance time as the standard tablet. It is suitable for patients with dysphagia, early morning dyskinesia, "on-off" phenomenon and end of dose dystonia
side effects: nausea, vomiting, hypotension and arrhythmia (occasionally) are common in peripheral side effects, which can be graally adapted after medication. Postprandial medication and addition of modoline can rece gastrointestinal symptoms. Central side effects include symptom fluctuation, dyskinesia and psychiatric symptoms. Symptom fluctuation and dyskinesia are common long-term complications, which usually occur after 4-5 years of medication. It is forbidden for patients with angle closure glaucoma and psychosis
(4) DA receptor agonists: Da includes five types of receptors, D1R and D2R subtypes are closely related to the treatment of PD. The characteristics of Dr agonists are as follows: (1) direct stimulation of postsynaptic DR in striatum, independent of DDC, can transform L-dopa into da; ② The plasma half-life was longer than that of compound dopa; ③ It may protect DA neurons in substantia nigra. The combination of early Dr agonist and compound DOPA can not only improve the curative effect, rece the dosage of compound dopa, but also rece or avoid the occurrence of symptom fluctuation or dyskinesia
indications: in the late stage of PD, patients with symptoms fluctuation or dyskinesia can be treated with compound dopa, and Dr agonist can alleviate or eliminate symptoms and rece the dosage of compound dopa. Due to the lack of DDC in substantia nigra striatum dopaminergic system in the later stage of the disease, exogenous L-dopa decarboxylation could not be converted into da. Compound DOPA was completely ineffective, and Dr agonist might be effective. The effect of DA receptor agonist alone is not good. It is generally advocated to use it in combination with compound L-dopa, and it can be used alone in early patients with young onset. We should start with small dose and graally increase the dose to obtain satisfactory curative effect without side effects. The side effects were similar to those of compound L-dopa, with low incidence of symptom fluctuation and dyskinesia, and high incidence of postural hypotension and psychiatric symptoms
commonly used preparations: bromocriptine and pergolide
① bromocriptine: activate D2 receptor, start 0.625mg/d, increase 0.625mg every 3-5 days, usually 7.5-15mg/d, three times; The side effects of levodopa are similar to those of levodopa. Illusion and hallucination are common. It is forbidden for patients with mental history. The relative contraindications include recent myocardial infarction, severe peripheral vascular disease and active peptic ulcer< (2) pergolide: activated D1 and D2 receptors, started at 0.025mg/d, increased by 0.025mg/d every 5 days, the general effective dose was 0.375-1.5mg/d, the maximum dose was not more than 2.0mg/d, reached the peak plasma concentration in 1-3 hours, the half-life was longer (average 30h), slightly stronger than bromocriptine in anti PD effect, and the action time was also longer. When bromocriptine treatment was ineffective, it might be effective to use pergolide instead< (3) trastalsr: piribedil is a selective D2 / D3 dopamine receptor agonist with a dose of 150-250 mg / d. it can stimulate D3R in midbrain cortex and limbic lobe pathway, improve tremor obviously, and also has effects on ankylosis and hypokinesia< (4) lisuride: it has a strong selective D2R agonist and a weak effect on D1R. It starts from a small dose, 0.05-0.1mg/d, and graally increases, with an average effective dose of 2.4-4.8mg/d; According to the action dose ratio, the effect is 10-20 times stronger than bromocriptine, the half-life is short (2.2 h on average), the action time is short, it is water-soluble, it can be used by intravenous or subcutaneous infusion pump, and it appears obvious "on-off" phenomenon in the treatment of compound dopa< (5) apomorphine: D1 and D2R agonists can significantly rece the "off period" state, and have obvious curative effect on symptom fluctuation, especially on "on-off" phenomenon and dystonia. The pen injection method takes effect 5-15 minutes after administration, and the effective action time is 60 minutes. Each administration is 0.5-2 mg, which can be used several times a day, Continuous subcutaneous perfusion with portable micro pump can make patients keep good motor function every day; It can also be administered through nasal cavity, but long-term administration can stimulate nasal mucosa< (6) cabaser: it has the longest half-life (70h) and the longest action time among all Dr agonists. It is suitable for patients with symptom fluctuation and dyskinesia caused by long-term application of compound dopa in the late stage of PD. The effective dose is 2-10mg / D, with an average of 4mg / D, only once a day, which is more convenient< (7) pramipexole (0.125 mg, 3 times / D, graally added to 0.5-1.0 mg, 3 times / D) and ropinirole (0.25 mg, 3 times / D, graally added to 2-4 mg, 3 times / D) are not ergot derivatives and have no ergot side effects. They are used in early or advanced PD, with low incidence of symptom fluctuation and dyskinesia, common confusion, hallucination and orthostatic hypotension
(5) MAO-B inhibitors: inhibit the decomposition of DA in neurons and increase the content of DA in brain. Combined with compound L-dopa, it can rece the dosage of L-dopa by about 1 / 4, delay the switch phenomenon, and has neuroprotective effect. Commonly used selegiline (deprenyl) 2.5 ~ 5mg, twice a day, should be taken in the morning, afternoon, evening can cause insomnia. Side effects include dry mouth, less stomach intake and postural hypotension. Patients with gastric ulcer should be cautious. Lazabemide (ro19-6327) is also a MAO-B inhibitor, but there are few reports on its clinical application
some scholars advocate that this kind of drug combined with vitamin E, called data-top scheme (), as a neuroprotective agent for early mild patients, may delay the progress of the disease. Vitamin E is a natural free radical scavenger, which has antioxidant effect. In the early stage of PD, especially in patients without treatment, vitamin E and amphetamine may slow down the degeneration of substantia nigra cells and delay the progress of the disease. In recent years, it has been advocated that amphetamine 2.5mg orally, once a day, graally increase to 2.5mg, twice a day, and then add
the DA neurons in the substantia nigra striatum system in the early stage of PD can compensate for the increase of DA synthesis. Physiotherapy (massage, hydrotherapy) and physical therapy (joint activity, walking, balance and language exercise, facial expression muscle exercise) are recommended to strive for the cooperation of patients' families, encourage patients to take more active exercise, and delay the drug treatment time as far as possible. If the disease affects the daily life and work of patients, drug treatment is needed< Drug therapy
2. Drug therapy is still the main treatment for PD at present. It can not prevent the development of PD by restoring the balance of Da and ACh neurotransmitter system in striatum, using anticholinergic and improving Da neurotransmitter function drugs to improve symptoms
principle of medication:
① starting from small dose, slowly increasing, try to use small dose to achieve satisfactory curative effect
② indivialized treatment plan, according to the patient's age, type and degree of symptoms, employment situation, drug price and affordability
3. Drugs should not be added blindly, should not be stopped suddenly, and should be taken for life< In recent years, adjuvant drugs such as Dr agonist, MAO-B inhibitor, catechol-O-methyltransferase (COMT) and so on, combined with compound dopa, can enhance the curative effect, rece the fluctuation of symptoms, and rece the dose of compound dopa, but the curative effect is not ideal when used alone. Therefore, we should weigh the advantages and disadvantages, and choose appropriate combination drugs
(1) anticholinergic drugs: effective for tremor and ankylosis, poor for motor retardation, suitable for younger patients with tremor. Artene was given orally 1-2mg, three times a day; Kemadrin 2.5mg orally, three times a day, graally increased to 20 ~ 30mg / d. Other drugs, such as benzotropin, cycrimine and Akineton, have similar effects to antam. Side effects include dry mouth, blurred vision, constipation, dysuria, and hallucinations and delusions in severe cases. It is forbidden in patients with glaucoma and prostatic hypertrophy, which can affect the memory function. It should be used with caution in elderly patients
(2) amantadine: it can promote the release of DA in nerve endings, prevent the reuptake, and has anticholinergic effect. It is a glutamate antagonist, which may have neuroprotective effect. It can slightly improve hyperactivity, rigidity and tremor, and can be used alone or in combination with antam in the early stage. The initial dose was 50mg, 2-3 times / D, and increased to 100mg, 2-3 times / d after one week, generally no more than 300mg / D, and no more than 200mg / D for the elderly. The effect can last for several months to one year. Less side effects, such as restlessness, blurred consciousness, lower limb reticular plaques, ankle edema and arrhythmia, should be used with caution in patients with renal insufficiency, epilepsy, severe gastric ulcer and liver disease, and should not be used in lactating women. Its derivative memantine hydrochloride can also be used
(3) L-dopa and compound L-dopa: L-dopa is an effective drug or gold indicator in the treatment of PD. As a precursor of Da, it can pass through the blood-brain barrier and be decarboxylated into Da after being ingested by brain dopaminergic neurons. It can improve symptoms and has a special effect on hypokinesia. Because more than 95% of L-dopa decarboxylate into DA in the peripheral blood, only about 1% of it enters the brain through BBB. In order to rece the peripheral side effects and enhance the curative effect, the compound preparation (compound L-dopa) made of L-dopa and DCI in the ratio of 4:1 is often used, and the dosage is 3 / 4 less than that of L-dopa
formulation of compound L-dopa: including standard tablets, controlled-release tablets, water-soluble tablets, etc. Standard tablets such as Madopar and Sinemet: ① Madopar was composed of L-dopa and Benserazide in the ratio of 4:1, Madopar 250 was L-dopa 200mg + Benserazide 50mg, Madopar 125 was L-dopa 100mg + Benserazide 25mg; The components of domestic dopasazide capsules are the same as those of Madopar; ② The ratio of L-dopa to carbidopa was 4 ∶ 1< There are two kinds of controlled-release agents:
① sinemetcr: L-dopa 200mg + carbidopa 50mg. The single-layer molecular matrix structure is added in the preparation. The drug is continuously dissolved to achieve sustained-release effect. The peak plasma concentration is reached 120-150min after oral administration; There is a scratch in the middle of the tablet, which can be divided into half tablets to maintain the sustained-release characteristics
② Madopar HBS: L-dopa 100mg + Benserazide 25mg and special excipients. When the capsules are dissolved, a hydration layer is formed on the surface of the drug matrix, which is graally released through dispersion
the water-soluble tablets were made up of 100 mg of L-dopa and 25 mg of Benserazide. Its characteristics are easy to dissolve in water, easy to take orally, rapid absorption, quickly reaching the treatment threshold concentration, so that PD patients in the "closed" state can quickly improve symptoms in a short time (about 10 minutes), and the effect maintenance time is basically the same as the standard tablets. The dosage form is suitable for PD patients with dysphagia or nasogastric tube insertion, inability to exercise in the morning, delayed "on" period, prolonged "off" period in the afternoon and dystonia at the end of the dosage
timing of medication: when to start the treatment of compound L-dopa is still controversial, and long-term medication will proce complications such as efficacy decline, symptom fluctuation and dyskinesia. Generally, the medication should be determined according to the patient's age, nature of work, type of disease, etc. Young patients should postpone the use of L-dopa and try to use other anti PD drugs in the early stage. When patients have to use L-dopa e to occupational requirements, they should be combined with other drugs to rece the dose of compound L-dopa. The elderly patients can choose L-dopa early, because the chance of motor complications is relatively less, and the tolerance of combined medication is poor
medication method: starting from a small dose, graally increasing according to the condition, maintaining with the lowest effective dose
① standard tablets: the dosage of compound L-dopa was 62.5mg (1 / 4 tablets), 2-3 times / D, and graally increased to 125mg, 3-4 times / D as needed; The maximum dose is not more than 250 mg, 3-4 times a day; Fasting (1 hour before meal or 2 hours after meal) was effective
② controlled release tablets: it has the advantages of recing the times of taking medicine, stable effective blood concentration, long action time and controlling the fluctuation of symptoms; The disadvantages are low bioavailability and slow onset. When standard tablets are converted into controlled-release tablets, the daily dose should be increased and taken in advance; It is suitable for patients with symptoms fluctuation or early mild disease
③ water soluble tablet: it is easy to dissolve in water, quickly absorbed, takes effect in 10 minutes, and has the same effect maintenance time as the standard tablet. It is suitable for patients with dysphagia, early morning dyskinesia, "on-off" phenomenon and end of dose dystonia
side effects: nausea, vomiting, hypotension and arrhythmia (occasionally) are common in peripheral side effects, which can be graally adapted after medication. Postprandial medication and addition of modoline can rece gastrointestinal symptoms. Central side effects include symptom fluctuation, dyskinesia and psychiatric symptoms. Symptom fluctuation and dyskinesia are common long-term complications, which usually occur after 4-5 years of medication. It is forbidden for patients with angle closure glaucoma and psychosis
(4) DA receptor agonists: Da includes five types of receptors, D1R and D2R subtypes are closely related to the treatment of PD. The characteristics of Dr agonists are as follows: (1) direct stimulation of postsynaptic DR in striatum, independent of DDC, can transform L-dopa into da; ② The plasma half-life was longer than that of compound dopa; ③ It may protect DA neurons in substantia nigra. The combination of early Dr agonist and compound DOPA can not only improve the curative effect, rece the dosage of compound dopa, but also rece or avoid the occurrence of symptom fluctuation or dyskinesia
indications: in the late stage of PD, patients with symptoms fluctuation or dyskinesia can be treated with compound dopa, and Dr agonist can alleviate or eliminate symptoms and rece the dosage of compound dopa. Due to the lack of DDC in substantia nigra striatum dopaminergic system in the later stage of the disease, exogenous L-dopa decarboxylation could not be converted into da. Compound DOPA was completely ineffective, and Dr agonist might be effective. The effect of DA receptor agonist alone is not good. It is generally advocated to use it in combination with compound L-dopa, and it can be used alone in early patients with young onset. We should start with small dose and graally increase the dose to obtain satisfactory curative effect without side effects. The side effects were similar to those of compound L-dopa, with low incidence of symptom fluctuation and dyskinesia, and high incidence of postural hypotension and psychiatric symptoms
commonly used preparations: bromocriptine and pergolide
① bromocriptine: activate D2 receptor, start 0.625mg/d, increase 0.625mg every 3-5 days, usually 7.5-15mg/d, three times; The side effects of levodopa are similar to those of levodopa. Illusion and hallucination are common. It is forbidden for patients with mental history. The relative contraindications include recent myocardial infarction, severe peripheral vascular disease and active peptic ulcer< (2) pergolide: activated D1 and D2 receptors, started at 0.025mg/d, increased by 0.025mg/d every 5 days, the general effective dose was 0.375-1.5mg/d, the maximum dose was not more than 2.0mg/d, reached the peak plasma concentration in 1-3 hours, the half-life was longer (average 30h), slightly stronger than bromocriptine in anti PD effect, and the action time was also longer. When bromocriptine treatment was ineffective, it might be effective to use pergolide instead< (3) trastalsr: piribedil is a selective D2 / D3 dopamine receptor agonist with a dose of 150-250 mg / d. it can stimulate D3R in midbrain cortex and limbic lobe pathway, improve tremor obviously, and also has effects on ankylosis and hypokinesia< (4) lisuride: it has a strong selective D2R agonist and a weak effect on D1R. It starts from a small dose, 0.05-0.1mg/d, and graally increases, with an average effective dose of 2.4-4.8mg/d; According to the action dose ratio, the effect is 10-20 times stronger than bromocriptine, the half-life is short (2.2 h on average), the action time is short, it is water-soluble, it can be used by intravenous or subcutaneous infusion pump, and it appears obvious "on-off" phenomenon in the treatment of compound dopa< (5) apomorphine: D1 and D2R agonists can significantly rece the "off period" state, and have obvious curative effect on symptom fluctuation, especially on "on-off" phenomenon and dystonia. The pen injection method takes effect 5-15 minutes after administration, and the effective action time is 60 minutes. Each administration is 0.5-2 mg, which can be used several times a day, Continuous subcutaneous perfusion with portable micro pump can make patients keep good motor function every day; It can also be administered through nasal cavity, but long-term administration can stimulate nasal mucosa< (6) cabaser: it has the longest half-life (70h) and the longest action time among all Dr agonists. It is suitable for patients with symptom fluctuation and dyskinesia caused by long-term application of compound dopa in the late stage of PD. The effective dose is 2-10mg / D, with an average of 4mg / D, only once a day, which is more convenient< (7) pramipexole (0.125 mg, 3 times / D, graally added to 0.5-1.0 mg, 3 times / D) and ropinirole (0.25 mg, 3 times / D, graally added to 2-4 mg, 3 times / D) are not ergot derivatives and have no ergot side effects. They are used in early or advanced PD, with low incidence of symptom fluctuation and dyskinesia, common confusion, hallucination and orthostatic hypotension
(5) MAO-B inhibitors: inhibit the decomposition of DA in neurons and increase the content of DA in brain. Combined with compound L-dopa, it can rece the dosage of L-dopa by about 1 / 4, delay the switch phenomenon, and has neuroprotective effect. Commonly used selegiline (deprenyl) 2.5 ~ 5mg, twice a day, should be taken in the morning, afternoon, evening can cause insomnia. Side effects include dry mouth, less stomach intake and postural hypotension. Patients with gastric ulcer should be cautious. Lazabemide (ro19-6327) is also a MAO-B inhibitor, but there are few reports on its clinical application
some scholars advocate that this kind of drug combined with vitamin E, called data-top scheme (), as a neuroprotective agent for early mild patients, may delay the progress of the disease. Vitamin E is a natural free radical scavenger, which has antioxidant effect. In the early stage of PD, especially in patients without treatment, vitamin E and amphetamine may slow down the degeneration of substantia nigra cells and delay the progress of the disease. In recent years, it has been advocated that amphetamine 2.5mg orally, once a day, graally increase to 2.5mg, twice a day, and then add
6. Introction: deepbrain mainly provides hardware manufacturers with five services: semantic skills store, AI human-computer dialogue engine, robot functional components, big data analysis and home Internet services. The team has developed the world's first blockchain based artificial intelligence operating system, deep brain chain, which uses blockchain technology to solve some pain points that are difficult to solve only by artificial intelligence technology
legal representative: Shuchang
time of establishment: April 6, 2017
registered capital: RMB 2 million
Instrial and commercial registration number: 310141000385257
enterprise type: limited liability company (invested or controlled by natural person)
address: 3 / F, building 1, No. 400, Fangchun Road, China (Shanghai) pilot Free Trade Zone
legal representative: Shuchang
time of establishment: April 6, 2017
registered capital: RMB 2 million
Instrial and commercial registration number: 310141000385257
enterprise type: limited liability company (invested or controlled by natural person)
address: 3 / F, building 1, No. 400, Fangchun Road, China (Shanghai) pilot Free Trade Zone
Hot content